Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Genitourinary 1

Conditions

Thymoma 1Small Cell Lung Carcinoma 1Kidney Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × vorolanib × Clear all
NCT03583086 2024-10-08

Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors

Vanderbilt-Ingram Cancer Center

Phase 1/2 Completed
88 enrolled 20 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Thymoma, Small Cell Lung Carcinoma

NCT06577961 2024-08-29

Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Not yet recruiting
37 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡